Drugs / TST002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05391776 | Apr 2022 → Apr 2023 | osteoporosis | HJB (Hangzhou) Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-07-31 | Suzhou Transcenta Therapeutics Co., Ltd. | Regulatory Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density transcenta.com ↗
announces that it has received approval from China Center for Drug Evaluation (CDE) to initiate Phase II clinical trial of TST002(Blosozumab). |
| 2023-05-17 | Suzhou Transcenta Therapeutics Co., Ltd. | Results Transcenta Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density transcenta.com ↗
TST002 (Blosozumab) was well tolerated and significantly increased BMD at day 85 following single intravenous injection at various doses. |
| 2021-09-27 | Suzhou Transcenta Therapeutics Co., Ltd. | Regulatory Transcenta Received IND Clearance from NMPA of its Anti-sclerostin Monoclonal Antibody TST002 transcenta.com ↗ |
| 2021-07-06 | Suzhou Transcenta Therapeutics Co., Ltd. | Regulatory Transcenta Announces NMPA Acceptance of IND Application of its Anti-Sclerostin Monoclonal Antibody TST002 transcenta.com ↗
Transcenta Holding Limited ("Transcenta"), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announces that NMPA has accepted IND application of its anti-sclerostin monoclonal antibody TST002. |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TST002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05391776 ↗ |
| Route | Intravenous | “single intravenous infusion of TST002” NCT05391776 ↗ |